featured
Type II RAF Inhibitor Tovorafenib for Relapsed/Refractory Pediatric Low-Grade Glioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nat. Med. 2023 Nov 17;[EPub Ahead of Print], LB Kilburn, DA Khuong-Quang, JR Hansford, D Landi, J van der Lugt, SES Leary, PH Driever, S Bailey, S Perreault, G McCowage, AJ Waanders, DS Ziegler, O Witt, PA Baxter, HJ Kang, TE Hassall, JW Han, D Hargrave, AT Franson, M Yalon Oren, H Toledano, V Larouche, C Kline, MS Abdelbaki, N Jabado, NG Gottardo, NU Gerber, NS Whipple, D Segal, SN Chi, L Oren, EEK Tan, S Mueller, I Cornelio, L McLeod, X Zhao, A Walter, D Da Costa, P Manley, SC Blackman, RJ Packer, K NysomFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.